Study of LY3954068 for Alzheimer's Disease

This study looks at the safety of a new drug called LY3954068 for people with early Alzheimer's Disease, a condition that affects memory. The study has two parts, A and B, and involves taking LY3954068 or a placebo (a substance with no active drug) through a spinal fluid injection. In Part A, each person will receive one dose, while in Part B, if it happens, there will be two doses. Part A lasts about 45 weeks, and if Part B is conducted, the whole study can last up to 73 weeks. There is also a chance to join another related study afterward, which could last up to 96 weeks.

• Each participant will receive either the study drug or a placebo.
• Part A lasts up to 45 weeks; Part B, if done, extends to 73 weeks.
• Participants need to have study partners for support during the study.